DEF 14A: Azitra Seeks Stockholder Approval for Director Elections and Incentive Plan Amendments

Azitra, Inc. is holding its 2024 Annual Meeting of Stockholders on November 20, 2024, to elect directors, approve amendments to the 2023 Stock Incentive Plan, and ratify the appointment of its independent accounting firm.

Summary

• Azitra, Inc. is convening its 2024 Annual Meeting of Stockholders virtually on November 20, 2024, at 11:00 a.m. ET.
• The meeting will address the election of four directors (Francisco D. Salva, Travis Whitfill, Barbara Ryan, and John Schroer) to serve until the next annual meeting.
• Stockholders will vote on two amendments to the Azitra, Inc. 2023 Stock Incentive Plan: one to increase the number of shares available for issuance and another to adopt an evergreen provision for automatic annual increases over the next 10 years.
• The meeting will also include a vote to ratify the appointment of Grassi & Co., CPAs, P.C. as the company's independent registered public accounting firm for the year ending December 31, 2024.
• Stockholders of record as of October 4, 2024, are entitled to vote.
• The company had 7,626,056 shares of common stock outstanding and entitled to vote as of October 4, 2024.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. The proposals are aimed at improving the company's ability to attract and retain talent, which is a positive sign. However, there are potential dilution risks associated with the proposed amendments.

Positives

• The proposed amendments to the 2023 Stock Incentive Plan aim to attract and retain qualified personnel by aligning their interests with those of the stockholders.
• The virtual meeting format is expected to provide expanded stockholder access and participation.
• The company is providing multiple avenues for stockholders to vote, including online, by mail, and in person at the virtual meeting.

Negatives

• Approval of the amendments to the 2023 Stock Incentive Plan could dilute existing stockholders' ownership.
• The evergreen provision allows for automatic annual increases in the number of shares available for issuance, which could lead to further dilution if not managed carefully.

Risks

• Failure to secure stockholder approval for the proposed amendments could limit the company's ability to attract and retain key personnel.
• The company's reliance on equity-based compensation may increase if the amendments are approved, potentially impacting future earnings.
• The forward-looking statements in the proxy statement are subject to risks and uncertainties that could cause actual results to differ materially.

Future Outlook

The company is seeking to ensure it has sufficient shares available under its incentive plan to attract and retain employees, officers, directors, and others upon whose judgment, initiative, and effort it depends.

Management Comments

• On behalf of the Board of Directors of Azitra, we thank you for your participation.
• We believe that a virtual meeting provides expanded stockholder access and participation and improved communications, while affording stockholders the same rights as if the meeting were held in person, including the ability to vote shares electronically during the meeting and ask questions in accordance with the rules of conduct for the meeting.

Industry Context

Equity compensation plans are a common tool in the biotechnology industry to attract and retain talent, aligning employee incentives with company performance and stockholder value.

Comparison to Industry Standards

• The evergreen provision, allowing for automatic annual increases in the share reserve, is a feature seen in some equity compensation plans to ensure continued flexibility.
• Companies like Moderna and BioNTech also utilize equity compensation plans to incentivize employees, but the specific terms and share allocations vary based on company size, stage, and industry benchmarks.
• The size of the proposed share increase (approximately 15% of outstanding shares) should be compared to industry averages for similar-sized biotech companies to assess its reasonableness.

Related Party Transactions

• In September 2022, Azitra issued unsecured convertible promissory notes in the aggregate principal amount of $4.35 million to five existing stockholders, including notes in the aggregate principal amount of $4 million to three funds under common control, namely Bios Fund III, LP, Bios Fund III QP, LP, and Bios Fund III NT, LP.
• In December 2019, Azitra entered into a Joint Development Agreement, or JDA, with Bayer pursuant to which Azitra agreed to the joint development of certain strains selected from its proprietary microbial library.
• In September 2020, Bayers venture capital group, LEAPS by Bayer, purchased $8 million of Azitra's Series B preferred stock.

Stakeholder Impact

• Approval of the proposed amendments could impact shareholders through potential dilution.
• Employees, officers, and directors could benefit from the increased flexibility in equity compensation.
• The ratification of the independent accounting firm ensures continued oversight of the company's financial reporting.

Next Steps

• Stockholders are urged to vote their shares via the Internet or by promptly marking, dating, signing, and returning the proxy card.
• The company will file a Form 8-K to publish the final voting results within four business days after the Annual Meeting.

Key Dates

Keywords

proxy statement, annual meeting, stockholders, directors, election, stock incentive plan, amendment, evergreen provision, Grassi & Co, independent accounting firm, executive compensation, corporate governance